ARDELYX, INC.

Lobbying for ARDELYX, INC.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate · $560,000.00 expenses · posted Apr 20, 2026

Lobbying activity 1

Health Issues

Access to innovative kidney treatments, ESRD PPS, coverage of oral only medications for people with ESRD, innovation, Drug pricing, Medicare access to pharmaceuticals.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.